2026 Clinical Neuromuscular Pathology Reading List

Reading List

Please click below to access the 2026 Clinical Neuromuscular Pathology reading list.

2026 Clinical Neuromuscular Pathology Reading List »

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Recognize typical and atypical clinical features of vasculitic myopathy, anti-Ku + myositis, and immune-mediated necrotizing myopathy and the pathogenic role of antibodies
  • Identify subtypes of inherited myopathies such as lipid storage and VCP myopathy
  • Explain the utility of RNA seq and major histocompatibility complex class II immunostaining
  • Discuss pathological mechanisms in peripheral neuropathies in general and in paraneoplastic neuropathies

Core Competencies

This UCNS C-cert activity covers the following core competencies:
  • Medical Knowledge
  • Patient Care
  • Practice-Based Learning and Improvement

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

2026 C-cert Activity Planner (Certification Council) Disclosures
All relevant financial relationships have been mitigated.

Clinical Neuromuscular Pathology Certification Examination Committee Contributors

Mazen Mohammad Dimachkie, MD, Chair, University of Kansas Medical Center 
Disclosures: Received consultancy fees, payment or honoraria for lectures, presentations, manuscript writing or educational events, and participated on a Data Safety Monitoring Board or Advisory Board for Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, Covance/Labcorp/Fortrea, Creton Bio Inc, CSL-Behring, Dianthus, Horizon, EMD Serono/Merck, Fortrea, Ig Society, Inc, Janssen, Medlink, Nuvig, Octapharma, Sanofi Genzyme, Shire Takeda, TACT/Treat NMD, Creyon Bio, and Vertex. Received consultancy fees, payment or honoraria for participating on a Data Safety Monitoring Board or Advisory Board for Covance/Labcorp/Fortrea. Received compensation from Oxford University Press, Wolters Kluwer Health/UpToDate, Elsevier. Received grants or research support from Abcuro, Alexion/ AstraZeneca, Alnylam Pharmaceuticals, Amicus, ArgenX, Biosensics, Bristol-Myers Squibb, Cabaletta Bio, Catalyst, CSL-Behring, EMD Serono, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Horizon Immnunovant , Mitsubishi Tanabe Pharma, MDA, NIH, Nkarta, Novartis, Octapharma, Orphazyme, Priovant, Ra Pharma/UCB Biopharma, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, and The Myositis Association. Holds/held patents, royalties, or other intellectual property interest from/with a discovery or technology relating to health care from Zevra Therapeutics. 

Ahmed Mohamed Attia El-Dokla, Vice Chair, MD, NY Neuromuscular Healthcare, PC 
Disclosures: Nothing to disclose. 

Lan Zhou, MD, PhD, Hospital for Special Surgery 
Disclosures: Nothing to disclose. 
 
Rocio Carolina Garcia Santibanez, MD, Emory Brain Health Center 
Disclosures: Nothing to disclose. 

Robert Bucelli, MD, Washington University School of Medicine in St. Louis 
Disclosures: Self and spouse have equity in Neuroquestions. Serves on advisory board and acts as a consultant for Biogen. Received compensation from Regeneron pharmaceuticals and one-time advisory board for Biogen. Received compensation from LGMD Masterclass as an invited speaker. Received compensation for serving as an expert witness – Rapp v Lebo and Calderon v Compton. Received compensation for serving as site PI for Biogen-sponsored trials in ALS and site PI for the Mitchell syndrome fund at WashU. 

Raghav Govindarajan, MD, St. Elizabeth Medical Group 
Disclosures: Received compensation for serving as an ad board member for Argenx, UCB, Alexion, Janssen, and Amgen. Received compensation for serving on speakers’ bureau for Argenx, UCB and Alexion. Received royalties from Taylor and Francis for book he authored. 

Teerin Liewluck, MD, Mayo Clinic – Rochester 
Disclosures: Received personal compensation in the range of $5000 to $9999 for serving on a scientific advisory board for Sarepta Therapeutics, Inc. Received publishing royalties from a publication relating to health care from Springer Nature. 

Suur Biliciler, MD, University of Texas Health Science Center 
Disclosures: Served on speaker’s bureau for UCB – for Rystiggo© and Zilbrysq©. Served on advisory board for Amgen. Received research support from Reclaiim (PI), Argenx (PI), and Dianthus Therapeutics. 

Anthony A. Amato, MD, Brigham and Women's Hospital 
Disclosures: Received compensation for serving on Medical Advisory Boards/Consultant for Abcuro, Argenx, EMD Serono, UCB, Horizon Therapeutics, OnoPharma, Alexion, Takeda, and Viridian Therapeutics. Received compensation from DSMB for Medpace, Cabaleta, and Sanofi. Received compensation as Assoc Editor of Neurology. Received compensation as expert witness for several cases for defense and plaintiff. Received NIH grant. 

Mohamed Kazamel, MD, Mayo Clinic in Arizona 
Disclosures: Served as an expert witness in a case against Clayton Polygraph services. Provided expert opinion on the effect of transthoracic sympathectomy surgeries on pupillary and other autonomic reflexes. Served as consultant for Lloyd, Gray, Whitehead & Monroe, Law Offices, Birmingham, AL. 

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326